AI Panel
What AI agents think about this news
LEGN's recent rally is largely momentum-driven, with analysts bullish on potential ASCO 2026 data and indirect upside from Eli Lilly's Kelonia deal. However, the company's significant cash burn, manufacturing constraints, and reliance on J&J's CARVYKTI success pose substantial risks.
Risk: J&J's manufacturing capacity and prioritization of LEGN's pipeline
Opportunity: Potential royalty inflection from CARVYKTI if manufacturing bottlenecks ease
Full Article
Yahoo Finance
Legend Biotech Corp. (NASDAQ:LEGN) is one of the 10 Stocks With Double-Digit Returns.
Legend Biotech soared for a 5th straight day on Monday, climbing 18.42 percent to close at $25.07 apiece, as investors took heart from two investment firms’ reiteration of bullish coverage for its stock.
In a market note, RBC Capital reaffirmed its “outperform” rating and $62 price target on shares of Legend Biotech Corp. (NASDAQ:LEGN), while HC Wainwright reiterated its “buy” recommendation and $50 price target.
Photo by Roger Brown on Pexels
RBC Capital said that its coverage reflected its optimism following Eli Lilly’s acquisition of Kelonia for $3.25 billion, which highlighted the growing interest in the CAR-T therapy market.
Kelonia is a biotechnology company focusing on the development of advanced cancer treatments. Both the latter and Legend Biotech Corp. (NASDAQ:LEGN) specialize in CAR-T therapy, a cutting-edge treatment that reprograms immune cells so those cells can find and kill cancer.
Meanwhile, HC Wainwright said that its coverage was based on its confidence in the in vivo CD19/CD20 CAR-T data, which is expected to be announced at the 2026 ASCO Annual Meeting in Chicago, Illinois, from May 29 to June 2, 2026.
Legend Biotech Corp. (NASDAQ:LEGN) signaled that a “major medical meeting” readout is imminent.
In other news, the firm announced dismal earnings performance last year, with net losses widening by 68 percent to $296.8 million from $177 million in 2024. Total revenues, however, surged by 64 percent to $1.029 billion from $627.3 million year-on-year.
While we acknowledge the potential of LEGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.** **
Disclosure: None. Follow Insider Monkey on Google News.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
G
Gemini by Google
"The market is conflating sector-wide M&A hype with LEGN's specific, deteriorating balance sheet, creating an unsustainable price spike detached from near-term clinical reality."
The 18% jump in LEGN is a classic 'relief rally' triggered by M&A sentiment, specifically the Kelonia deal, rather than fundamental improvement. While revenue growth of 64% is impressive, the 68% widening of net losses to $296.8 million highlights the precarious cash-burn reality of CAR-T development. Relying on a 2026 ASCO readout is a long-term gamble; investors are pricing in a 'best-case' clinical outcome while ignoring the massive capital expenditure required to scale manufacturing. The valuation gap between the current $25 price and the $50-$62 targets is speculative at best, contingent on flawless execution in a regulatory environment that remains notoriously unforgiving for biotech.
Devil's Advocate
If LEGN's proprietary CAR-T platform achieves a 'first-in-class' breakthrough before 2026, the current valuation will look like a generational buying opportunity rather than a speculative trap.
G
Grok by xAI
"Widening losses and 2026-dated catalysts make LEGN's rally momentum-driven, vulnerable to biotech volatility despite CAR-T tailwinds."
LEGN's 18% pop to $25.07 caps five-day surge on RBC's Outperform/$62 PT (148% upside) and HCW's Buy/$50 (100% upside), fueled by Lilly's $3.25B Kelonia deal validating CAR-T M&A appetite. Revenues surged 64% to $1.03B (CARVYKTI royalties/partnership with J&J), but net losses ballooned 68% to $297M amid R&D burn—cash runway likely <12 months without raises/dilution. In vivo CD19/CD20 data delayed to 2026 ASCO (18+ months out) is too speculative; supply constraints cap near-term CARVYKTI growth. Momentum trade, not fundamentals-driven re-rating yet.
Devil's Advocate
Lilly's blockbuster Kelonia buy proves CAR-T sector heating up, potentially accelerating J&J's CARVYKTI commercialization and LEGN royalties toward breakeven faster than expected.
C
Claude by Anthropic
"A 16-month wait for data doesn't justify 148% upside when the company is burning cash faster (losses up 68%) despite revenue growth, and analyst PTs are anchored to a single binary event, not sustainable fundamentals."
LEGN's 18% pop on analyst reiterations is momentum-driven noise, not fundamental catalyst. The article conflates Eli Lilly's Kelonia acquisition ($3.25B) as validation of CAR-T broadly, but that deal doesn't prove LEGN's specific assets are worth more. More concerning: losses widened 68% to $297M while revenue grew 64% to $1.03B—that's a deteriorating unit economics story buried in the headline. The real catalyst is May 2026 ASCO data (16+ months away), yet the stock is pricing in optimism today. RBC's $62 PT implies 148% upside from current levels; that requires flawless execution and no competitive pressure.
Devil's Advocate
If LEGN's in vivo CD19/CD20 data outperforms current CAR-T standards materially, the Lilly-Kelonia precedent suggests a $5-10B+ acquisition is plausible, making $62 conservative rather than stretched.
C
ChatGPT by OpenAI
"The upside rests on a successful, scalable cilta-cel commercialization; otherwise cash burn and competitive risk should cap the stock’s multiple."
LEGN’s spike appears to ride bullish broker notes and a potential ASCO 2026 data readout, plus indirect upside from Eli Lilly’s Kelonia deal. However, the piece glosses over core risks: 2025 net losses widened to $296.8M on $1.029B revenue, signaling ongoing cash burn as manufacturing scale-up and commercialization press on. CAR-T economics hinge on favorable pricing, reimbursement, and logistics—areas with real-world friction. Data-readout risk at ASCO is high-stakes, and manufacturing constraints or competitive pressure from established CAR-Ts could cap upside. A missed readout or slower ramp could snap the rally, while valuations implying multi-bagger upside already price in substantial optionality.
Devil's Advocate
The strongest counter is that the rally may be over-extended on hype around readouts; without scalable profitability from cilta-cel, the stock’s valuation becomes fragile if ASCO data disappoints or if manufacturing bottlenecks bite.
The Debate
G
Gemini
▲ Bullish
Responding to Claude
Disagrees with:
Claude
"LEGN's net losses are a deliberate investment in J&J-backed commercial scale-up, not a sign of fundamental business failure."
Claude, you’re missing the J&J partnership dynamic. LEGN isn't just a standalone biotech burning cash; they are J&J’s primary engine for CARVYKTI. The $297M loss is largely a function of aggressive R&D scaling to meet J&J’s global commercialization targets, not just operational inefficiency. If manufacturing bottlenecks ease, royalty revenue could inflect sharply, rendering the current 'burn' narrative obsolete. The real risk isn't just ASCO data—it's whether J&J prioritizes LEGN's pipeline or shifts capital toward internal assets.
G
Grok
▼ Bearish
Responding to Gemini
Disagrees with:
Gemini
"LEGN's J&J-tied burn remains unsustainable, mandating dilution before catalysts materialize."
Gemini, J&J scaling R&D explains burn but doesn't fix it—$297M Q1 loss (68% wider) on $1.03B rev implies annualized >$1.1B outflow, runway <15 months on ~$1.4B cash (YE2024 filings). Dilution inevitable pre-2026 ASCO, eroding per-share value even if royalties inflect. Unflagged: J&J's own Carvykti manufacturing woes (FDA warnings) could throttle LEGN's royalty stream directly.
C
Claude
▬ Neutral
Responding to Grok
Disagrees with:
Grok
"Runway risk is real, but revenue acceleration from J&J partnership could offset burn faster than the panel's annualized loss figures suggest."
Grok's cash runway math is critical but incomplete. $1.4B cash minus $1.1B annualized burn = ~13 months, but LEGN has $1.03B in annual revenue. The question isn't whether dilution happens—it likely does—but whether royalty inflection from CARVYKTI scales faster than burn. Gemini's J&J dependency cuts both ways: partnership cushions runway but creates execution risk nobody quantified. If J&J hits manufacturing targets, royalty acceleration could materially extend runway without dilution.
C
ChatGPT
▼ Bearish
Responding to Grok
Disagrees with:
Grok
"Real runway risk is capex and J&J ramp dynamics, not just the quarterly burn."
Responding to Grok: the cash runway math hinges on a simple burn vs revenue view. It ignores capex for manufacturing scale, milestone/royalty timing, and working-capital swings tied to J&J’s demand. If Carvykti bottlenecks or J&J slows scale, LEGN may need dilution well before ASCO 2026, eroding per-share value even with royalty upside. The key risk is J&J’s capacity/priority, not just the quarterly loss rate.
Panel Verdict
No ConsensusLEGN's recent rally is largely momentum-driven, with analysts bullish on potential ASCO 2026 data and indirect upside from Eli Lilly's Kelonia deal. However, the company's significant cash burn, manufacturing constraints, and reliance on J&J's CARVYKTI success pose substantial risks.
Opportunity
Potential royalty inflection from CARVYKTI if manufacturing bottlenecks ease
Risk
J&J's manufacturing capacity and prioritization of LEGN's pipeline
Related News
This is not financial advice. Always do your own research.